Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
159 hedge funds and large institutions have $195M invested in Antares Pharma, Inc. in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 46 reducing their positions, and 14 closing their positions.
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
24% more capital invested
Capital invested by funds: $157M → $195M (+$38.1M)
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
3% more funds holding
Funds holding: 154 → 159 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less call options, than puts
Call options by funds: $311K | Put options by funds: $386K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
+$10M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.1M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$3.63M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.15M |
| 2 |
Morgan Stanley
New York
|
-$2.56M |
| 3 |
Millennium Management
New York
|
-$2.12M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.77M |
| 5 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$1.75M |
ATRS Hedge Fund Activity: Q2 2020 in Review
159 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2020, worth a combined $195M — up 24% from $157M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATRS positions and 14 closed out — a net gain of 6 holders — while 56 added to existing stakes and 46 trimmed.
The largest buyer was Centric Wealth Management, opening a new position worth an estimated $10M. The largest seller was Renaissance Technologies, cutting an estimated $3.15M.
- 159 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2020, up from 154 in Q1 2020.
- Funds reported $195M of Antares Pharma, Inc. stock for Q2 2020, up 24% quarter-over-quarter.
- 20 funds opened new Antares Pharma, Inc. positions in Q2 2020 and 14 closed out, a net change of +6 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2020 was Centric Wealth Management, an estimated $10M added.
- The largest Antares Pharma, Inc. seller in Q2 2020 was Renaissance Technologies, an estimated $3.15M sold.
Based on aggregated 13F filings for Q2 2020.